Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Zeidan AM, et al. Among authors: arnan m. Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5. Lancet Haematol. 2024. PMID: 38065203 Clinical Trial.
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
Geissler K, Koristek Z, Del Castillo TB, Novák J, Rodríguez-Macías G, Metzelder SK, Illes A, Mayer J, Arnan M, Keating MM, Krauter J, Lunghi M, Fracchiolla NS, Platzbecker U, Santini V, Sano Y, Oganesian A, Keer H, Lübbert M. Geissler K, et al. Among authors: arnan m. Br J Haematol. 2024 Nov;205(5):1734-1745. doi: 10.1111/bjh.19741. Epub 2024 Sep 23. Br J Haematol. 2024. PMID: 39313917 Clinical Trial.
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
de Botton S, Fenaux P, Yee K, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove C, Jonas BA, Khwaja A, Legrand O, Peterlin P, Arnan M, Blum W, Cilloni D, Hiwase DK, Jurcic JG, Krauter J, Thomas X, Watts JM, Yang J, Polyanskaya O, Brevard J, Sweeney J, Barrett E, Cortes J. de Botton S, et al. Among authors: arnan m. Blood Adv. 2023 Jul 11;7(13):3117-3127. doi: 10.1182/bloodadvances.2022009411. Blood Adv. 2023. PMID: 36724515 Free PMC article.
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto LM, Guttke C, Gyan E, Hamad N, Herrera P, Hultberg A, Jacobs J, Johnson AJ, Langlois A, Ma X, Martinelli G, Arnan M, Müller R, Nottage K, Ofran Y, Özcan M, Samoilova O, Tolbert JA, Trudel GC, Xiu L, Vey N, Wei AH. Pabst T, et al. Among authors: arnan m. Lancet Haematol. 2023 Nov;10(11):e902-e912. doi: 10.1016/S2352-3026(23)00207-7. Lancet Haematol. 2023. PMID: 37914483 Clinical Trial.
Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial.
Laporte-Amargos J, Carmona-Torre F, Huguet M, Puerta-Alcalde P, Rigo-Bonnin R, Ulldemolins M, Arnan M, Del Pozo JL, Torrent A, Garcia-Vidal C, Pallarès N, Tebé C, Muñoz C, Tubau F, Padullés A, Sureda AM, Carratalà J, Gudiol C. Laporte-Amargos J, et al. Among authors: arnan m. Clin Microbiol Infect. 2025 Feb;31(2):211-219. doi: 10.1016/j.cmi.2024.10.006. Epub 2024 Oct 19. Clin Microbiol Infect. 2025. PMID: 39433124 Free article. Clinical Trial.
Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia.
Jiménez-Vicente C, Arribas I, Pomares H, Ramil G, Castaño-Diez S, Pérez-Valencia AI, Sturla AL, López-Guerra M, Martinez-Roca A, Zugasti I, Guijarro F, Cortés-Bullich A, Merchán B, Triguero A, Monge I, Tuca A, Oñate G, Garrido A, Sierra J, Arnan M, Esteve J, Díaz-Beyá M; Spanish CETLAM Group. Jiménez-Vicente C, et al. Among authors: arnan m. Haematologica. 2025 Jan 23. doi: 10.3324/haematol.2024.286589. Online ahead of print. Haematologica. 2025. PMID: 39844754 Free article.
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
Oñate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M, Diaz-Beya M, Vives S, Zamora L, Sampol A, Coll R, Salamero O, Cervera M, Garcia A, Vall-Llovera F, Garcia-Avila S, Bargay J, Ortin X, Iranzo E, Guijarro F, Pratcorona M, Nomdedeu JF, Esteve J, Sierra J. Oñate G, et al. Among authors: arnan m. Blood Cancer J. 2025 Jan 11;15(1):4. doi: 10.1038/s41408-024-01205-5. Blood Cancer J. 2025. PMID: 39799145 Free PMC article.
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.
Vives S, Quintela D, Morgades M, Cano-Ferri I, Serrano A, Acuña-Cruz E, Cervera M, Díaz-Beyá M, Vidriales B, Raposo-Puglia JÁ, Arnan M, Garrido A, Balerdi A, Cabello AI, Herrera-Puente P, Serrano J, Coll R, Tormo M, López-Marín J, García-Ávila S, Casado MS, Padilla I, Rodríguez-Macías G, Calbacho M, Puchol A, Hernández A, Torres M, Costilla L, Colorado MM, Martínez-Cuadrón D, Esteve J, Montesinos P; CETLAM and PETHEMA Groups. Vives S, et al. Among authors: arnan m. Cancers (Basel). 2024 Nov 30;16(23):4028. doi: 10.3390/cancers16234028. Cancers (Basel). 2024. PMID: 39682214 Free PMC article.
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Rodríguez-Arbolí E, Rodríguez-Veiga R, Soria-Saldise E, Bergua JM, Caballero-Velázquez T, Arnán M, Vives S, Serrano J, Bernal T, Martínez-Sánchez P, Tormo M, Rodríguez-Medina C, Herrera-Puente P, Lavilla-Rubira E, Boluda B, Acuña-Cruz E, Cano I, Cáceres S, Ballesteros J, Falantes J, Martínez-Cuadrón D, Pérez-Simón JA, Montesinos P; PETHEMA Group. Rodríguez-Arbolí E, et al. Among authors: arnan m. Cancer. 2025 Jan 1;131(1):e35618. doi: 10.1002/cncr.35618. Epub 2024 Oct 30. Cancer. 2025. PMID: 39476204 Free PMC article. Clinical Trial.
Arsenic trioxide-induced peripheral neuropathy: prospective clinical and neurophysiological evaluation in a cohort of patients with acute promyelocytic leukemia.
Cellini A, Salvalaggio A, Velasco R, Arnan M, Cacciavillani M, Riva M, Trentin L, Pomares H, Lessi F, Briani C. Cellini A, et al. Among authors: arnan m. Leuk Lymphoma. 2024 Dec;65(13):2060-2063. doi: 10.1080/10428194.2024.2391899. Epub 2024 Aug 13. Leuk Lymphoma. 2024. PMID: 39138968 No abstract available.
100 results